The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Profusa to Acquire PanOmics Platform for $30M and Partners with Mayo Clinic

Key Facts

1Profusa signed a Letter of Intent to acquire the PanOmics multi-omics diagnostics platform for $30 million.

2The deal aims to integrate biosensing technologies with molecular diagnostics and precision medicine.

Profusa (PFSA) has announced a strategic expansion into the molecular diagnostics market by signing a Letter of Intent to acquire the PanOmics platform for $30 million. The acquisition from BioInsights LLC aims to integrate Profusa's biosensing technologies with advanced molecular diagnostics and precision medicine. This move is designed to establish a scalable multi-product franchise that combines real-time biochemistry monitoring with multi-omics diagnostics. In addition to the acquisition, Profusa revealed a new partnership with the Mayo Clinic focused on developing diagnostic applications for pancreatic cancer. The collaboration leverages Mayo Clinic's clinical expertise to advance the company's precision medicine initiatives. While the deal remains at the Letter of Intent stage, it represents a significant entry into a multi-billion dollar healthcare sector.